Sign in to continue:

Thursday, February 12th, 2026
Market UpdatesUS stocks

Elon Musk’s Support for Weight-Loss Drugs Could Propel Eli Lilly Stock: Analysts See 40% Upside

Posted on December 13, 2024 at 12:00 pm (GMT+8)

747
Views
Share on Facebook
Share on Twitter

A Presidential Boost for GLP-1s?

Eli Lilly’s stock, recently hit by postelection volatility, could see a remarkable turnaround, driven in part by high-profile endorsements. Bernstein analysts point to positive signals that suggest the pharmaceutical giant could thrive under the new U.S. administration.

The Backdrop:
The company’s stock slid over 6% following President-elect Donald Trump’s announcement of Robert F. Kennedy Jr., a vaccine skeptic, as his pick for Health and Human Services. But Bernstein analyst Courtney Breen argues the selloff was overdone, especially for Eli Lilly, a leader in GLP-1 weight-loss drugs like Mounjaro and Zepbound.

Two Key Catalysts:

A Strategic Dinner: Eli Lilly CEO David Ricks recently attended a dinner with Trump and Kennedy, alongside other industry leaders. Breen sees this as a signal for potential collaboration on health initiatives.

Elon Musk’s Endorsement: Musk, tasked with a government efficiency initiative by Trump, tweeted his support for making GLP-1 drugs “super low cost,” emphasizing their unparalleled potential to enhance public health.

Why Eli Lilly Stands Out:
Breen highlights the company’s U.S. base and scalability as advantages over competitors like Novo Nordisk. With a 38.2% upside potential and an outperform rating, Eli Lilly is well-positioned for growth.

Despite challenges, Eli Lilly shares are up 35% this year, marking eight consecutive years of gains. Could Musk’s influence and the administration’s focus on health initiatives drive the next surge?

Thank you

Related Posts

🚀 Midday Market Movers: ETFs Rally, HSI Climbs, AI & Property Stocks in Spotlight
minichart
September 9, 2025

🚀 Midday Market Movers: ETFs Rally, HSI Climbs, AI & Property Stocks in Spotlight HK:07366.HK:XI2CSOPTSLAHK:09366.HK:XI2CSOPTSLA-UHK:07226.HK:XL2CSOPHSTECHHK:03406.HK:PA TECHSELECTHK:07747.HK:XL2CSOPSMSN 📈 ETFs led midday gains with XI2CSOPTSLA jumping 4.1% to HK$19.8, while its U.S. counter XI2CSOPTSLA-U rose 2.6%....

Market UpdatesSingapore SGX stocks

Venture Corporation Limited Honored with Prestigious Supplier Excellence Award from Lam Research
minichart
September 27, 2024

Date: 27 September 2024 Broker: Lim & Tan Securities Award Recognition Venture Corporation Limited, priced at $14.16 as of 27 September 2024, received the prestigious Supplier Excellence Award at Lam Research Corporation’s 2024 ceremony....

Market UpdatesSingapore SGX stocks

text Download Copy code 1Okay, here’s an attempt to create an SEO title and answer potential user questions based on the provided document: 2 3**SEO title:** 4SEO title: SATS Ltd (SATS SP): Embedded Resilience & FY26F Outlook – CGS International Analysis 5 6**Analysis based on the document:** 7 8Based on the document provided, here’s a summary of key points and potential user questions with answers: 9 10**Key Points:** 11 12* **Company:** SATS Ltd (SATS SP) 13* **Recommendation:** Reiterate Add 14* **Analyst:** TAY Wee Kuang and LIM Siew Khee, CGS International 15* **Key Themes:** Embedded resilience, cargo market share gains, FY26F outlook 16* **Target Price:** S\$3.60 17* **ESG:** Rated B- by LSEG 18 19**Potential User Questions & Answers:** 20 21**Q: What is the overall recommendation for SATS Ltd?** 22A: CGS International reiterates an “Add” recommendation for SATS Ltd. [[1]] 23 24**Q: What is the target price for SATS Ltd, and who set it?** 25A: The target price is S\$3.60, set by CGS International. [[1]] 26 27**Q: What is the basis for the target price?** 28A: The target price is DCF-based (Discounted Cash Flow), with a WACC of 12.2%. [[1]] 29 30**Q: What are the key factors driving the “Add” recommendation?** 31A: The key factor is SATS’s growing market share in cargo handling, which is expected to support earnings growth in FY26F, even with potential global cargo demand weakness. [[1]] 32 33**Q: What is SATS’s ESG rating?** 34A: SATS has an ESG combined score of B- by LSEG. [[1, 5]] 35 36**Q: What were SATS’s 4QFY3/25 financial results?** 37A: SATS reported a 4QFY3/25 net profit of S\$38.7m (+18.3% yoy). Revenue was S\$1.48bn (+10.4% yoy). [[1]] 38 39**Q: What are the potential risks to SATS’s performance?** 40A: Downside risks include margin compression from weaker operating leverage due to softening cargo volumes and a decline in the aviation travel industry due to an economic downturn. [[1]] 41 42**Q: What is the dividend payout?** 43A: SATS declared a final DPS of 3.5 Scts, bringing FY25 total DPS to 5.0 Scts, representing a payout ratio of 30.6%. [[1]] 44 45**Q: What is the earnings growth outlook?** 46A: The report anticipates a 3-year earnings CAGR of 15.0%. [[1]] 47 48**Q: Has the analyst revised earnings estimates?** 49A: Yes, FY26F-27F EPS estimates have been increased by 7.9-8.5%. FY28F estimates are introduced. [[1]] 50 51**Q: What are the catalysts for a potential re-rating?** 52A: Potential re-rating catalysts include an expanded footprint for cargo operations supporting new contract wins and a faster step-up in utilization of its new central kitchens across China and India. [[1]] 53 54**Q: What is SATS’s market capitalization?** 55A: The market cap is US\$3,444m / S\$4,428m. [[1]] 56 57**Q: Who are the major shareholders of SATS?** 58A: Temasek Holdings is a major shareholder, holding 40.4%. [[1]] 59 60**Q: What is SATS’s revenue in Mar-25A?** 61A: SATS’s revenue in Mar-25A is S\$5,821 million. [[1]] 62 63**Q: What are the peers of SATS?** 64A: Airports of Thailand is a peer. [[4]] 65 66**Q: What is the forecast dividend yield for Mar-26F?** 67A: The forecast dividend yield for Mar-26F is 1.85%. [[1]]
minichart
May 26, 2025

CGS International May 26, 2025 SATS Ltd: Embedded Resilience to Tide Through FY26F Key Takeaways from SATS Ltd’s 4QFY3/25 Performance SATS Ltd reported a 4QFY3/25 net profit of S\$38.7m, which is an 18.3% year-over-year...